Pharmafile Logo

Orphan Drugs

- PMLiVE

A rare opportunity

Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing

Shire Basingstoke

Shire completes $32bn Baxalta merger

Creates world leading rare diseases specialist

AstraZeneca AZ global R&D corporate HQ

AZ gets orphan status for selumetinib in thyroid cancer

Drug already in phase III testing for KRAS-mutant advanced NSCLC

- PMLiVE

Paywatch and the market access waters

Understanding and responding to payers’ needs has become priority number one for pharma

- PMLiVE

A new route to market

Despite regulation becoming more harmonised, SME expansion still presents complex access challenges

- PMLiVE

Stepping up to payer-driven market access

Giving the industry an opportunity to secure payers’ endorsements of its products by clearly illustrating product value

- PMLiVE

GSK unveils access plan for low-income countries

Will file patents for its drugs according to each country’s 'economic maturity'

- PMLiVE

Med comms has a ‘big role to play’ in market access

HCA meeting hears communications can assist companies with the process

Webinar Recording: The Art of Storytelling in Pharma Market Research

Effectively communicating research insights is a major focus for today’s market researcher, particularly in global healthcare. It’s not enough now just to present the research evidence. We must tell the...

Research Partnership

- PMLiVE

Should We Care About Rare Diseases? By Alastair Kent

Alastair Kent, OBE, the Director of Genetic Alliance UK and chair of Rare Disease UK tells us why it’s so important to care about rare disease and why we should...

Say Communications

- PMLiVE

The price is right?

To market new innovation against a backdrop of restricted budgets, companies must work hard - and start early

- PMLiVE

Baxalta agrees to $32bn Shire takeover

Deal will  create one of the industry's top rare disease firms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links